Search research articles
Contact Us
Filters
Showing results (81-90 of 101) with videos related to
Page
of 11
Sort By:
Blood Cancer Journal
|
June 17, 2017
Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit
M A Dimopoulos, M Roussou, M Gavriatopoulou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 9, 2022
Corrigendum to "Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up'": [Ann Oncol Volume 33, Issue 1, January 2022, Page 117]
M A Dimopoulos, P Moreau, E Terpos, et al.
Annals of Hematology
|
April 27, 2002
Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response
N Viniou, E Terpos, A Galanopoulos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 3, 2021
Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322]
M A Dimopoulos, P Moreau, E Terpos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 29, 2017
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P Moreau, J San Miguel, P Sonneveld, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 11, 2003
Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma
M A Dimopoulos, A Pouli, K Zervas, et al.
Leukemia
|
September 3, 2010
The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group
E Terpos, M A Dimopoulos, O Sezer, et al.
Blood Cancer Journal
|
June 17, 2017
Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib
E Kastritis, M Gavriatopoulou, M Roussou, et al.
Journal of Hematology & Oncology
|
January 18, 2018
Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel
J Caers, B Paiva, E Zamagni, et al.
Journal of Internal Medicine
|
February 7, 2019
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension
S Bringhen, A Milan, M D'Agostino, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 101) with videos related to
Sort By:
Page
of 11
Blood Cancer Journal
|
June 17, 2017
Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit
M A Dimopoulos, M Roussou, M Gavriatopoulou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 9, 2022
Corrigendum to "Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up'": [Ann Oncol Volume 33, Issue 1, January 2022, Page 117]
M A Dimopoulos, P Moreau, E Terpos, et al.
Annals of Hematology
|
April 27, 2002
Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response
N Viniou, E Terpos, A Galanopoulos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 3, 2021
Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322]
M A Dimopoulos, P Moreau, E Terpos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 29, 2017
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P Moreau, J San Miguel, P Sonneveld, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 11, 2003
Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma
M A Dimopoulos, A Pouli, K Zervas, et al.
Leukemia
|
September 3, 2010
The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group
E Terpos, M A Dimopoulos, O Sezer, et al.
Blood Cancer Journal
|
June 17, 2017
Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib
E Kastritis, M Gavriatopoulou, M Roussou, et al.
Journal of Hematology & Oncology
|
January 18, 2018
Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel
J Caers, B Paiva, E Zamagni, et al.
Journal of Internal Medicine
|
February 7, 2019
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension
S Bringhen, A Milan, M D'Agostino, et al.
Page
of 11